| Daptomycin Plus β-Lactam Combination Therapy for Methicillin-resistant Staphylococcus aureus Bloodstream Infections: A Retrospective, Comparative Cohort Study SCJ Jorgensen, EJ Zasowski, TD Trinh, AM Lagnf, S Bhatia, N Sabagha, ... Clinical Infectious Diseases 71 (1), 1-10, 2020 | 79 | 2020 |
| Evaluation of eravacycline: a novel fluorocycline S Alosaimy, JC Abdul‐Mutakabbir, R Kebriaei, SCJ Jorgensen, MJ Rybak Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 40 (3 …, 2020 | 49 | 2020 |
| Real-world multicenter analysis of clinical outcomes and safety of meropenem-vaborbactam in patients treated for serious gram-negative bacterial infections S Alosaimy, SCJ Jorgensen, AM Lagnf, S Melvin, RP Mynatt, TJ Carlson, ... Open Forum Infectious Diseases 7 (3), ofaa051, 2020 | 45 | 2020 |
| Cefiderocol: a novel Siderophore cephalosporin against multidrug‐resistant gram‐negative pathogens JC Abdul‐Mutakabbir, S Alosaimy, T Morrisette, R Kebriaei, MJ Rybak Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 40 (12 …, 2020 | 44 | 2020 |
| Preliminary, Real-world, Multicenter Experience With Omadacycline for Mycobacterium abscessus Infections T Morrisette, S Alosaimy, JV Philley, C Wadle, C Howard, AJ Webb, ... Open Forum Infectious Diseases 8 (2), ofab002, 2021 | 42 | 2021 |
| Real-world, multicenter experience with meropenem-vaborbactam for gram-negative bacterial infections including carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa S Alosaimy, AM Lagnf, T Morrisette, MR Scipione, JJ Zhao, ... Open forum infectious diseases 8 (8), ofab371, 2021 | 40 | 2021 |
| Early experience with eravacycline for complicated infections S Alosaimy, KC Molina, KC Claeys, J Andrade, J Truong, MA King, ... Open Forum Infectious Diseases 7 (5), ofaa071, 2020 | 34 | 2020 |
| Clinical pharmacy practice in Saudi Arabia: Historical evolution and future perspective HA Badreldin, S Alosaimy, A Al‐jedai Journal of the American College of Clinical Pharmacy 3 (5), 920-929, 2020 | 33 | 2020 |
| Exploring anti-MRSA activity of chitosan-coated liposomal dicloxacillin A Alshamsan, FS Aleanizy, M Badran, FY Alqahtani, H Alfassam, ... Journal of microbiological methods 156, 23-28, 2019 | 30 | 2019 |
| The evolving reduction of vancomycin and daptomycin susceptibility in MRSA—salvaging the gold standards with combination therapy T Morrisette, S Alosaimy, JC Abdul-Mutakabbir, R Kebriaei, MJ Rybak Antibiotics 9 (11), 762, 2020 | 25 | 2020 |
| Early multicenter experience with imipenem-cilastatin-relebactam for multidrug-resistant gram-negative infections N Rebold, T Morrisette, AM Lagnf, S Alosaimy, D Holger, K Barber, ... Open Forum Infectious Diseases 8 (12), ofab554, 2021 | 24 | 2021 |
| Monotherapy with vancomycin or daptomycin versus combination therapy with β-lactams in the treatment of methicillin-resistant Staphylococcus aureus bloodstream infections: a … S Alosaimy, NL Sabagha, AM Lagnf, EJ Zasowski, T Morrisette, ... Infectious Diseases and Therapy 9, 325-339, 2020 | 23 | 2020 |
| Annual alveolar bone loss in older adults taking oral bisphosphonate: a retrospective cohort study M Helmi, S AlOsaimy, JM Goodson, H Hasturk, ZS Natto BMC Oral Health 19, 1-8, 2019 | 20 | 2019 |
| Effect of a pharmacist-driven medication management intervention among older adults in an inpatient setting S Alosaimy, A Vaidya, K Day, G Stern Drugs & aging 36, 371-378, 2019 | 16 | 2019 |
| Vancomycin Area Under the Curve to Predict Timely Clinical Response in the Treatment of Methicillin-resistant Staphylococcus aureus Complicated Skin and Soft … S Alosaimy, KP Murray, EJ Zasowski, T Morrisette, AM Lagnf, TP Lodise, ... Clinical Infectious Diseases 73 (11), e4560-e4567, 2021 | 14 | 2021 |
| Clinical outcomes of eravacycline in patients treated predominately for carbapenem-resistant Acinetobacter baumannii S Alosaimy, T Morrisette, AM Lagnf, LM Rojas, MA King, BM Pullinger, ... Microbiology Spectrum 10 (5), e00479-22, 2022 | 12 | 2022 |
| COVID-19: before the fall, an evidence-based narrative review of treatment options N Rebold, D Holger, S Alosaimy, T Morrisette, M Rybak Infectious Diseases and Therapy 10, 93-113, 2021 | 12 | 2021 |
| Impact of COVID-19 pandemic on training of pharmacy residents and fellows: Results from a national survey of postgraduate pharmacy trainees WJ Moore, A Webb, T Morrisette, LK Sullivan, S Alosaimy, S Hossain, ... American Journal of Health-System Pharmacy 78 (12), 1104-1111, 2021 | 10 | 2021 |
| Risk Factors for Carbapenem-Resistant Enterobacterales Clinical Treatment Failure N Rebold, AM Lagnf, S Alosaimy, DJ Holger, P Witucki, A Mannino, ... Microbiology Spectrum 11 (1), e02647-22, 2023 | 9 | 2023 |
| A comparison of daptomycin alone and in combination with ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bacteremia complicated by septic … T Morrisette, AM Lagnf, S Alosaimy, MJ Rybak European Journal of Clinical Microbiology & Infectious Diseases 39, 2199-2203, 2020 | 9 | 2020 |
